Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Lexaria raises about $5.9 million through warrant exercises while issuing new Series A and B warrants that may add further equity over time.
Rhea-AI Summary
Lexaria Bioscience (LEXX) has closed the previously announced cash exercise of certain outstanding warrants for an aggregate 453,969 common shares at a reduced exercise price of $12.92 per share, generating approximately $5.9 million in gross proceeds before fees.
In connection with the exercise, Lexaria issued new unregistered Series A and Series B warrants, each series covering up to 453,969 shares at an exercise price of $12.67 per share. The Series A warrants are immediately exercisable and expire five years after the effective date of a planned resale registration statement, while the Series B warrants are immediately exercisable and expire eighteen months after that effective date. Lexaria expects to use the net proceeds for working capital and general corporate purposes.
Positive
- Gross proceeds of ~$5.9 million from warrant exercises before fees
- Immediate cash exercise of 453,969 warrants at $12.92 per share
- New Series A and B warrants for up to 907,938 shares at $12.67 could provide additional future funding
Negative
- Issuance of 453,969 new shares from warrant exercise creates equity dilution
- New Series A and B warrants for up to 907,938 additional shares add potential future dilution
- Exercise price reduced to $12.92 from original prices up to $45.90, lowering potential capital per share
News Explained
The completed exercise dilutes existing ownership, while replacement warrants leave further share issuance contingent on future exercise.
The completed cash exercise issued
Against the latest reported
The new warrants were offered in a private placement, meaning securities offered to selected investors outside a public offering, and their underlying shares require effective registration or an exemption for U.S. resale.
The effective S-1 and S-3 registrations cited for the exercised shares register securities for sale; registration itself does not issue shares, so the new warrants represent potential rather than completed additional share issuance.
Sources and calculations
- Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds (2026-09-09)
- Dilution (2026-07-17)
- Private placement / PIPE (2026-07-17)
- Form S-1 purpose (2026-07-17)
- Form S-3 purpose (2026-07-17)
- Lexaria 2026 third-quarter fundamentals (2026Q3)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate ($3,500,000 + $142,103) / ($1,635,020 / 92) = 204.9 days
Key Figures
- Warrants exercised
- 453,969 shares
- Previously outstanding warrants exercised for cash
- Reduced exercise price
- $12.92 per share
- Price paid for the warrant exercise
- Gross proceeds
- Approximately $5.9 million
- Before placement agent fees and other offering expenses
- Series A warrants
- 453,969 shares at $12.67 per share
- Immediately exercisable; expire five years from resale registration effectiveness
- Series B warrants
- 453,969 shares at $12.67 per share
- Immediately exercisable; expire eighteen months from resale registration effectiveness
Previous Offering Reports
-
Immediate cash exercise of outstanding warrants with new Series A and Series B warrants
-
Registered direct offering closed with common shares and concurrently issued warrants
-
Registered direct offering announced with concurrent private placement of warrants
-
Registered direct offering closed with additional warrants issued in private placement
-
Registered direct offering announced with concurrently issued unregistered warrants
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
warrants financial
private placement financial
form s-1 regulatory
form s-3 regulatory
resale registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The shares of common stock issued upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-277863), Form S-3 (File No. 333-283484), Form S-1 (File No. 333-290862), and Form S-1 (File No. 333-292469).
In consideration for the immediate exercise of the warrants for cash, the Company issued new unregistered Series A warrants to purchase up to an aggregate of 453,969 shares of common stock (the "Series A Warrants") and short-term Series B warrants (the "Series B Warrants," and together with the Series A Warrants, the "New Warrants") to purchase up to an aggregate of 453,969 shares of common stock. The Series A Warrants have an exercise price of
The gross proceeds to the Company from the exercise of the warrants were approximately
The New Warrants described above were offered in a private placement and, along with the shares of common stock issuable upon exercise of the New Warrants, have not been registered under the Securities Act of 1933, as amended (the "1933 Act"), or applicable state securities laws. Accordingly, the New Warrants and shares of common stock issuable upon the exercise of the New Warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the 1933 Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission ("SEC") as soon as practicable covering the resale of the shares of common stock issuable upon exercise of the New Warrants (the "Resale Registration Statement").
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering, the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext. 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire